Osiris completes enrollment in adult mesenchymal stem cell trial to treat pulmonary disease.
The company says the double-blind, placebo-controlled study is evaluating safety and efficacy of Prochymal in conjunction with the standard of care for improving pulmonary function in patients with moderate to severe COPD. Patients were randomized to receive either Prochymal or placebo at a 1.1 ration. Measurements used in the trial to detect potential improvements in subjects treated with the drug include pulmonary function tests, exercise capability, and quality of life assessments. In addition, exacerbations and hospitalizations due to COPD will be monitored for both safety and efficacy. Patients will be evaluated over the course of two years following initial Prochymal or placebo infusion.
Osiris says Prochymal is currently being evaluated in three double-blind, placebo controlled Phase III studies, including steroid refractory Graft vs. Host Disease (GvHD) and Crohn's disease. The drug has been granted fast track status by the FDA for all three of the indications. In addition, the drug has obtained Orphan Drug status for GvHD by the FDA and the European Medicines Agency.
Contact: Web site: www.Osiris.com
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Oct 1, 2008|
|Previous Article:||NIH Director Elias Zerhouni announces he will step down at the end of October.|
|Next Article:||Bioheart announces 35 US heart failure centers are engaged in Phase II/III trial using myogenic cells.|